Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)

This is an investigator-initiated, single-arm, exploratory clinical study.The study population consisted of non-operative Locally Advanced Esophageal Cancer . The purpose of this study was to evaluate the efficacy and safety of Concurrent Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Patients With Locally-advanced Esophageal Squamous Cell Cancer.

Inclusion Criteria:Age:18-75 years of age;Histologically confirmed squamous cell carcinoma;locally-advanced ,medical inoperability, technical irresectability, or patient refusal to surgery;Eastern Cooperative Oncology Group (ECOG) performance status:0-2;Able to eat a semi-liquid diet;Less than 20% weight loss within 6 months;Adequate hepatic function, renal function, hematologic function and coagulation function;Documented informed consent.Exclusion Criteria:Distant metastasis;Known malignancy diagnosed or require active treatment in the last 5 years, except for cancers that can be cured by surgery including cervical cancer in situ, basal or squamous cell skin cancer, breast ductal carcinoma in situ, localized prostate cancer;Prior thoracic irradiation, chemotherapy, or lobectomyKnown diseases or conditions that are contraindicated for radiotherapy or surgery;Allergy to the research medications;Pregnant women or women preparing for pregnancy;Diagnosis of autoimmune disease or history of chronic autoimmune diseaseAbsence of informed consent because of psychological, family, social and other factors;Patients with comorbidities (chronic pulmonary disease, poorly controlled hypertension, unstable angina, myocardial infarction within 6 months, unstable mental disorders requiring therapy).